Morrisville, NC – According to filings with the U.S. Securities and Exchange Commission, Istari Oncology is raising $70,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Matthew Stober played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded in 2016 and supports the research and clinical development of PVSPRIO and other technologies discovered at Duke University.

To learn more about Istari Oncology, visit http://istarioncology.com/

Contact:
Matthew Stober, President and Chief Executive Officer
919-245-7662

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved